A decongestant is disclosed consisting essentially of active components of from about 2 g to about 10 g of vegetable oil, from about 0.1 g to about 5 g of aloe vera, from about 3 mg to about 150 mg of zinc, from about 10 mg to about 1000 mg of vitamin C, from about 2,000 USP Units to about 70,000 USP Units of vitamin A, from about 20 IU to about 500 IU of vitamin E, from about 10 mg to about 300 mg of vitamin B-6, from about 50 mcg to about 2000 mcg of biotin, and from about 0.3 g to about 2 g of fruit pectin, per about 1 liter of the decongestant. The balance is carriers and solvents. The zinc is supplied as one or more therapeutic compounds of zinc.
A decongestant composition and method are provided for treatment of symptoms associated with respiratory disorders. The composition in the form of an aqueous solution which comprises aloe vera, castor oil, sodium metasilicate and calcium chloride as the essential active components. The decongestant can be topically applied to the nasal or bronchial passages from dispensers containing spray means or inhalation mist means.
A stable, non-irritating composition and method for treating, without side effects, acute or chronic rhinosinusitis and its associated upper airway symptoms. The composition and treatment are useful for relieving the symptoms, and shortening the duration, of acute or chronic rhinosinusitis. The composition comprises a therapeutically effective solution having a pH of about 6.0, of ascorbic acid and caffeine, in combination with other soluble vitamins, natural ingredients and preservatives in a pharmaceutically acceptable carrier. The method includes the steps of preparing and administering the composition to the nasal membranes of a patient in the form of a nasal spray or drops.
An aqueous, flavored, topical, nasal decongestant composition containing an amount of oxymetazoline or a pharmaceutically acceptable salt thereof e.g., oxymetazoline HCl sufficient to effect nasal decongestion and an amount of a fruity flavor e.g. cherry flavor, sufficient to mask the medicinal after-taste of the composition, together with an aqueous carrier.
An aqueous, flavored, topical, nasal decongestant composition containing an amount of oxymetazoline or a pharmaceutically acceptable salt thereof, e.g., oxymetazoline HCl sufficient to effect nasal decongestion and an amount of a fruity flavor e.g. cherry flavor, sufficient to mask the medicinal after-taste of the composition, together with an aqueous carrier.
There is provided a composition for the nasal delivery of a drug suitable for the treatment of erectile dysfunction to a mammal wherein the composition is adapted to provide an initial rise in plasma level followed by a sustained plasma level of the drug.
